The biotechnology company has advanced its Alzheimer's disease diagnostic test, adapting it to a widely used hospital format and securing a royalty agreement with a partner.
The biotechnology company has secured a global licensing agreement for its Optimer binders to be used as vaccine adjuvants in the swine health sector, creating a new revenue stream.
The biotechnology company will present new data on its proprietary Optimer® delivery vehicle at an upcoming industry conference.
The life sciences company has released new corporate and investor materials, providing an overview of its strategy and financial metrics.
The biotechnology firm reported a 133% increase in revenue and reduced losses, alongside progress in its Optimer programmes and partnerships. However, it remains unprofitable with ongoing cash burn concerns.
The biotechnology company has announced a change in major shareholding, with Dowgate Group Limited now holding 4.96% of the voting rights.
The biotechnology company will announce its interim results and host an investor presentation next month.
The biotechnology company has issued new shares to a Non-Executive Director as part of their compensation package.
The biotechnology company reports substantial revenue growth and significant commercial progress across its key development programmes, including advancing trials with Unilever and validating a biomarker for Alzheimer's disease.
Biotechnology company Aptamer Group sees director increase stake